On August 11, 2026, the Centers for Medicare & Medicaid Services issued a final rule barring federal Medicaid and CHIP funds from covering puberty blockers, hormone therapy, and surgery for transgender minors. It takes effect October 13, 2026. It is not a blanket ban — states may still use their own funds — but it could reshape access for low-income youth.
This development sits within the broader story of transgender legal and policy history that we track across our Transgender History & Education hub. Below is a fact-based summary of what the rule does, who it affects, and what happens next — drawn from the independent health-policy organization KFF and the text of the rule itself.
What did the new Medicaid rule actually do?
The rule prohibits federal Medicaid and CHIP dollars from paying for certain gender-affirming services for young people. According to KFF, it specifically bars federal funds from covering puberty blockers, hormone therapy, and surgery (which is very rarely used among minors) for enrollees under 18 in Medicaid and under 19 in the Children’s Health Insurance Program. Notably, it does not prohibit coverage of counseling or psychotherapy provided as part of gender-affirming care.
CMS issued the regulation on August 11, 2026, published it in the Federal Register on August 13, and it follows a proposed rule the agency put forward in December 2025. In the rule’s own language, CMS groups the restricted treatments under the term “sex-rejecting procedures” — the agency’s phrasing, which differs from the terminology used by the medical organizations quoted below. During the public comment period, CMS received nearly 35,000 comments; of the roughly 11,000 that were posted, the agency reports that more than 90% opposed the change.
Is this a nationwide ban on gender-affirming care?
No — it restricts federal funding, not the care itself. The rule expressly permits states to continue covering these services using state-only dollars. KFF compares the structure to the long-standing Hyde Amendment, under which federal Medicaid funds cannot pay for most abortions but individual states may use their own money to cover them more broadly, as 21 states currently do.
Whether access actually changes for a given family therefore depends heavily on where they live. About half of U.S. states already restrict youth access to gender-affirming care. KFF estimates there are roughly 130,000 young transgender people enrolled in Medicaid or CHIP who live in states without such restrictions — the group most directly affected if their state chooses not to backfill the funding.
When does the rule take effect, and is there a transition period?
The rule takes effect October 13, 2026 — 60 days after its August 13 publication in the Federal Register. The most significant change from the December proposal is a limited tapering period: for enrollees already receiving hormone therapy as of the effective date, federal funds may continue to cover that therapy “for a tapering period of up to 6 months.” CMS said it added the provision “after careful consideration of the comments” to give patients and providers “a reasonable opportunity to phase off these medications.” The tapering allowance does not apply to puberty blockers.
How does this fit the recent history of transgender policy?
The rule is one entry in a fast-moving period of policy change. KFF notes that the number of states limiting youth access to gender-affirming care rose from just 4 in 2023 to 27 today, and that a range of federal administrative actions have targeted this care. For readers tracing how these measures connect over time, our Reference Library history section and research collection place the current moment in longer context, and our News & Commentary section follows developments as they unfold.
It is worth noting the medical context CMS’s action sits against: major professional organizations — including the American Medical Association, the American Academy of Pediatrics, and the American Psychological Association — describe gender-affirming care as a recommended, evidence-based practice. Supporters of the rule frame it as appropriate caution around treatments for minors; opponents, including numerous medical groups, characterize it as a restriction not grounded in that clinical consensus. Both positions are part of the public record.
What are the financial stakes for states?
The direct dollar figures are comparatively small. CMS estimates that Medicaid spent about $31 million on the now-prohibited services for enrollees under 19 in 2023 — roughly 0.003% of all Medicaid spending that year. KFF observes that this makes the cost of a state absorbing these services with its own funds relatively modest, though the political and administrative decision to do so will vary state by state. You can read the full analysis in KFF’s Quick Take on the final rule.
What happens next?
Legal challenges appear likely, though as of August 20, 2026, no suit has been filed against the final rule. When the proposed rule was released in December 2025, multiple state attorneys general and the ACLU stated they opposed the policy and planned to fight it, per KFF. A press officer for Massachusetts Attorney General Andrea Joy Campbell has since said her office intends to challenge the final rule.
KFF notes that access could narrow further once the tapering period ends, with the sharpest effects in states that neither restrict the care nor fund it with state dollars. It is worth reading this rule alongside a decision that ran the other way the same week: a federal court in Massachusetts vacated a separate rule that would have stripped gender-affirming care of its essential-health-benefit status under the ACA. The two actions cover different programs and different populations, and they point in opposite directions.
Frequently asked questions
Does the rule ban gender-affirming care for adults?
No. The rule addresses federal Medicaid and CHIP funding for enrollees under 18 (Medicaid) and under 19 (CHIP). It does not change coverage rules for adults.
Can states still pay for this care?
Yes. The rule restricts federal financial participation but expressly allows states to cover the services using state-only funds, similar to how some states fund abortion coverage outside the federal Hyde Amendment.
Does it stop all gender-affirming services?
No. It targets federal funding for puberty blockers, hormone therapy, and surgery for minors. It does not prohibit coverage of counseling or psychotherapy provided as part of gender-affirming care.
What is the tapering period?
For enrollees already on hormone therapy as of the effective date, federal funds may continue covering that therapy for up to six months. The allowance does not extend to puberty blockers.
How many young people could be affected?
KFF estimates roughly 130,000 young transgender people are enrolled in Medicaid or CHIP in states that do not already restrict access — the group most directly affected if their state does not fund the care itself.
Is the rule final, or could it change?
It is a final rule, but state attorneys general and the ACLU have signaled legal challenges, so litigation could shape its implementation.
Continue Exploring
More in Politics